BIIB

Biogen
D

BIIB

132.000
USD
-1.17
(-0.88%)
مغلق
حجم التداول
24,617
الربح لكل سهم
15
العائد الربحي
-
P/E
13
حجم السوق
19,341,673,824
أصول ذات صلة
ABBV
ABBV
-1.530
(-0.80%)
189.200 USD
AMGN
AMGN
1.79
(0.60%)
298.52 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
INCY
INCY
0.300
(0.44%)
68.470 USD
JNJ
JNJ
0.570
(0.37%)
156.110 USD
LLY
LLY
0.55
(0.07%)
779.65 USD
MRK
MRK
-1.370
(-1.66%)
81.010 USD
PFE
PFE
0.110
(0.43%)
25.440 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
المزيد
الأخبار المقالات

العنوان: Biogen

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.